MAFG and urinary bladder cancer: Further investigations have shown that high expression of MAFG-AS1 correlates with poor prognosis in bladder cancer patients, while those with low expression exhibit greater sensitivity to adjuvant chemotherapy involving cisplatin and gemcitabine.